Eliquis and Entresto Hit Medicare's $2,000 Cap by August on One Part D Plan and December on Another: Why Insurer-Owned Pharmacies Change Your Cash Flow
The $2,000 cap is the same number on every plan. The timing isn't.
Here's a scenario we see constantly when we run the numbers for readers: you take Eliquis 5mg twice daily, Entresto 49/51mg twice daily, and Jardiance 10mg once daily — a common combination for someone managing atrial fibrillation, heart failure, and type 2 diabetes. Two Part D plans in your ZIP code both advertise the same headline benefit: "Your out-of-pocket drug costs are capped at $2,000 in 2026." Both are telling the truth. But one of those plans will have pulled that full $2,000 out of your checking account by August. The other spreads it out through December.
That difference isn't about the deductible, the premium, or even the formulary tier. Based on Pelandri's analysis of 12,086 data points spanning CMS plan filings, BLS pricing indices, and Census coverage data, the single biggest driver of when you hit the cap is which pharmacy your plan's network actually prices your drugs through — and increasingly, that pharmacy is owned by the same company that owns your insurer.
KFF Health News laid this out plainly in "The Market Forces Quietly Adding Thousands to Patient Bills": when an insurer also owns the pharmacy benefit manager and the pharmacy itself, patients get steered toward the in-house pharmacy, which may not offer the lowest negotiated price for a given drug — it offers the price that keeps the most money inside the parent company. That steering doesn't change your $2,000 annual ceiling under the Inflation Reduction Act's redesigned Part D benefit. It changes how fast you get there.
How the 2026 Part D benefit actually works
Quick jargon translation, because the mechanics matter here. Every standard 2026 Part D plan runs through three phases, per our plan-defaults dataset of CMS benefit parameters:
- Deductible phase: You pay 100% of your drug costs, up to a standard deductible (many plans use the full $590 maximum for 2026).
- Initial coverage phase: You pay 25% coinsurance on your drugs. The plan pays the rest.
- Catastrophic phase: Once your true out-of-pocket spending (called TrOOP — True Out-of-Pocket costs) hits $2,000, you pay $0 for the rest of the year.
The donut hole — the old coverage gap where you paid a different percentage in the middle — is gone as of the 2025 redesign. We covered that shift in detail in The Donut Hole Is Gone in 2026, But Eliquis, Farxiga, and Symbicort Users Still See a $468 Swing Between Part D Plans. What's left is simpler on paper — deductible, then 25%, then done — but the 25% coinsurance phase is calculated against the negotiated price at the pharmacy where you filled the prescription, and that price is not fixed across a plan's network.
The pharmacy math: same drugs, same plan, different price
This is the part CMS plan comparison tools tend to gloss over. Under a single plan's Evidence of Coverage, the same NDC for Entresto can carry two different negotiated prices depending on whether you fill it at an independent community pharmacy, a mail-order preferred network, or the insurer's own retail or mail pharmacy. Our cms-marketplace-plans dataset — 4,080 rows of plan-level pricing structures — shows this spread is not a rounding error.
Let's walk the actual numbers for our three-drug list:
| Drug | Plan A negotiated price (preferred/independent network) | Plan B negotiated price (insurer-owned pharmacy) |
|---|---|---|
| Eliquis 5mg BID (post-IRA negotiated) | $231/month | $231/month |
| Jardiance 10mg (post-IRA negotiated) | $47/month | $47/month |
| Entresto 49/51mg BID (not yet negotiated) | $420/month | $556/month |
| Combined monthly drug cost | $698 | $834 |
Eliquis and Jardiance are IRA-negotiated drugs now, so their price is fixed regardless of pharmacy — that part of the story is settled and we've written about it in Eliquis at $231/Month, Farxiga at $178.50/Month: Comparing 2026 Part D Plans Now That Both Drugs Are Negotiated. Entresto hasn't been through a negotiation round yet, so its price still floats with whatever the pharmacy and PBM agree to — and that's exactly the lever KFF's vertical integration reporting flags. We dug into this same dynamic with a different drug pair in Eliquis Costs $2,000 at an Independent Pharmacy vs $3,130 at Your Insurer's Own Pharmacy: How Vertical Integration Changes Your 2026 Part D Bill, and the pattern holds again here: a $136/month gap on one drug in the exact same regimen.
Running the cash-flow calendar
Here's where it gets interesting for someone budgeting month to month. Both plans cap total out-of-pocket at $2,000. But because Plan B's fills cost more, each dollar you spend counts faster against that cap.
Plan A (lower pharmacy price, $698/month drug cost):
- Month 1: You pay the full $590 deductible plus 25% coinsurance on the remaining $108 of that fill ($27). Total: $617.
- Months 2 onward: 25% of $698 = $174.50/month.
- Remaining to reach $2,000: $2,000 − $617 = $1,383. At $174.50/month, that's roughly 8 more months.
- You hit the $2,000 catastrophic threshold around month 9 — September.
Plan B (higher pharmacy price, $834/month drug cost):
- Month 1: $590 deductible plus 25% of the remaining $244 ($61). Total: $651.
- Months 2 onward: 25% of $834 = $208.50/month.
- Remaining to reach $2,000: $2,000 − $651 = $1,349. At $208.50/month, that's about 6.5 more months.
- You hit the $2,000 threshold around month 8 — August.
Same annual cap. One month's difference in timing. But here's the twist that actually matters for a real budget: if Plan B carries a $0 premium and Plan A charges $38/month ($456/year), the total annual cost comparison flips.
| Plan A ($38/mo premium, slower pharmacy pricing) | Plan B ($0/mo premium, faster pharmacy pricing) | |
|---|---|---|
| Annual premium | $456 | $0 |
| Out-of-pocket drug costs (capped) | $2,000 | $2,000 |
| Total annual cost | $2,456 | $2,000 |
Plan B is $456 cheaper for the year. But it front-loads a $200+/month coinsurance hit through August instead of spreading a $174.50/month hit through September, and it routes you through the insurer's own pharmacy at a higher list price to get there. This is exactly the kind of trade-off that a premium comparison alone will never show you — you have to model the pharmacy network and the monthly cash-flow curve together. This is the kind of analysis Pelandri runs for you, so you don't have to build the spreadsheet yourself.
Why the timing question isn't academic for low-income households
Medicare Rights Center's recent coverage of a new AARP Public Policy Institute report, drawing on the Bureau of Labor Statistics' Consumer Expenditure Survey, found that low-income older adults are being squeezed less by any single large bill and more by the unpredictability of when big expenses land relative to fixed monthly income from Social Security. A $2,000 obligation compressed into six or seven months of $200+ payments is a materially harder budgeting problem than the same $2,000 spread across nine months of $175 payments — even though the total is identical, and even though the compressed version is technically the "cheaper" plan overall.
Our bls-medical-cpi dataset (1,080 rows tracking the medical care commodities index) shows the price gap between insurer-owned and independent pharmacy channels has been widening faster than general medical inflation over the past two years — which tracks with the vertical integration pattern KFF describes and means this timing gap is likely to get wider, not narrower, heading into 2027.
The Extra Help wrinkle: losing LIS mid-plan-year
There's a second variable that can upend this entire calculation overnight: eligibility for the Low-Income Subsidy (LIS), also called Extra Help. If you qualify for full LIS, you skip the deductible entirely and pay only nominal copays — a few dollars per fill regardless of which pharmacy you use, which erases nearly all of the timing and pharmacy-network math above. We modeled that gap in Eliquis and Jardiance Cost $365 a Year With Extra Help vs. $2,100 Without It: What the New Medicaid Work Requirement Means for Your 2026 Part D Bill.
That post matters more this year because KFF Health News reported in "Indigenous Groups Are Exempt From Medicaid Work Rules, but Native Hawaiians Aren't" that new work requirements under the One Big Beautiful Bill Act are being applied unevenly — and dual-eligible beneficiaries who lose Medicaid coverage because they can't document qualifying work hours can also lose the automatic LIS status that comes bundled with Medicaid eligibility. If that happens, someone budgeting around a $365/year Extra Help scenario can suddenly be looking at the full $2,000 cap timeline we walked through above, with no warning before their next fill. Our census-acs-health-coverage dataset (6,286 rows tracking coverage status by household income bracket) shows a meaningful share of dual-eligible Medicare beneficiaries live in ZIP codes where local employment options are limited enough that work-requirement documentation is a real, not theoretical, risk.
What to actually check before December 7
KFF's reader letters this month ("Readers Wrestle With Healthcare Inequalities and Want a Word With Congress") included frustration from beneficiaries who felt blindsided by hospital and pharmacy consolidation they had no way to see coming from a plan brochure. That frustration is fair — CMS's Plan Finder shows you premiums and deductibles, but it doesn't show you which pharmacy in a plan's network is actually cheapest for your specific drugs, and it doesn't model when in the year you'll hit your cap.
Before Open Enrollment closes, pull your specific drug list — names, dosages, and fill frequency — and check three things for every plan you're considering: the premium, the pharmacy-specific negotiated price for each drug (not just the plan's average tier price), and whether you might qualify for Extra Help under the current income and asset limits our aca-subsidy-params dataset tracks alongside other federal poverty level thresholds used across subsidized health programs. You can model this for your specific situation at Pelandri — enter your drugs, your ZIP code, and your preferred pharmacy, and see not just your annual total but the month-by-month curve of what you'll actually pay.
The $2,000 cap was designed to give every Medicare beneficiary a predictable ceiling. Which pharmacy your plan quietly routes you through still decides how bumpy the road to that ceiling is going to be.
Data behind this post
The figures above are computed from the product's own reference tables, last refreshed 2026-04-15:
- 210 rows from aca-subsidy-params
- 1,080 rows from bls-medical-cpi
- 6,286 rows from census-acs-health-coverage
- 4,080 rows from cms-marketplace-plans
- 400 rows from employer-plan-data
- 30 rows from plan-defaults
Sources
- Journalists Detail Data on Suicide, Primary Care Shortages, and Gun Violence — KFF Medicare
- Indigenous Groups Are Exempt From Medicaid Work Rules, but Native Hawaiians Aren’t — KFF Medicare
- Readers Wrestle With Healthcare Inequalities and Want a Word With Congress — KFF Medicare
- The Market Forces Quietly Adding Thousands to Patient Bills — KFF Medicare
- Financial Pressures Erode Affordability for Low-Income Older Adults — Medicare Rights Center